tetano
Editor, Senior Moderator
Cureus
. 2022 Jul 27;14(7):e27353.
doi: 10.7759/cureus.27353. eCollection 2022 Jul.
Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
Gurdeep Singh[SUP] 1 [/SUP], Alsayed Osman[SUP] 1 [/SUP], Robert Ryad[SUP] 1 [/SUP], Phuong Nguyen[SUP] 1 [/SUP], Raphael Itzkowitz[SUP] 1 [/SUP], Edward Maharam[SUP] 1 [/SUP]
Affiliations
Abstract
Multisystem inflammatory syndrome in adults (MIS-A) is a systemic inflammatory syndrome that presents with a heterogeneous collection of signs and symptoms in adults. Here we present a case of a 38-year-old male who met the case definition of the MIS-A four weeks after a mild, symptomatic case of coronavirus disease 2019 (COVID-19) despite receiving casirivimab-imdevimab (REGEN-COV). Given the presence of signs and symptoms consistent with MIS-A, the patient was started on intravenous immune globulin (IVIG) and IV methylprednisolone. He promptly demonstrated clinical improvement over the next several days.
Keywords: atypical rash; covid 19; immune therapy mediated myocarditis; mis-a; systemic disease.
. 2022 Jul 27;14(7):e27353.
doi: 10.7759/cureus.27353. eCollection 2022 Jul.
Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
Gurdeep Singh[SUP] 1 [/SUP], Alsayed Osman[SUP] 1 [/SUP], Robert Ryad[SUP] 1 [/SUP], Phuong Nguyen[SUP] 1 [/SUP], Raphael Itzkowitz[SUP] 1 [/SUP], Edward Maharam[SUP] 1 [/SUP]
Affiliations
- PMID: 36046289
- PMCID: PMC9417327
- DOI: 10.7759/cureus.27353
Abstract
Multisystem inflammatory syndrome in adults (MIS-A) is a systemic inflammatory syndrome that presents with a heterogeneous collection of signs and symptoms in adults. Here we present a case of a 38-year-old male who met the case definition of the MIS-A four weeks after a mild, symptomatic case of coronavirus disease 2019 (COVID-19) despite receiving casirivimab-imdevimab (REGEN-COV). Given the presence of signs and symptoms consistent with MIS-A, the patient was started on intravenous immune globulin (IVIG) and IV methylprednisolone. He promptly demonstrated clinical improvement over the next several days.
Keywords: atypical rash; covid 19; immune therapy mediated myocarditis; mis-a; systemic disease.